Intraventricular dexmedetomidine decreases cerebral blood flow during normoxia and hypoxia in dogs

Anesthesia and Analgesia

Volumn 84, Issue 1, 1997, Pages 139-147

  McPherson, Robert W ^a   Koehler, Raymond C ^a   Kirsch, Jeffrey R ^a   Traystman, Richard J ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; DEXMEDETOMIDINE;

ANIMAL EXPERIMENT; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; BRAIN HYPOXIA; BRAIN PERFUSION; DOG; DRUG DISTRIBUTION; DRUG EFFECT; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANOXIA; BRAIN; CEREBROSPINAL FLUID; CEREBROVASCULAR CIRCULATION; DOGS; IMIDAZOLES; INJECTIONS, INTRAVENTRICULAR; MEDETOMIDINE; OXYGEN; OXYGEN CONSUMPTION;

EID: 0031032584     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199701000-00026     Document Type: Article

References (34)

1. Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. 1. Sedation, ventilation, and metabolic rater. Anesthesiology 1992;77:1125-33.
2. Zornow MH, Fleishcer JE, Scheller MS, et al. Dexmedetomidine, an alpha 2-adrenergic agonist, decreases cerebral blood flow in the isoflurane-anesthetized dog. Anesth Analg 1990;70:624-30.
3. 2-Adrenergic agonist effects on normocapnic and hypercapnic cerebral blood flow in the dog are anesthetic dependent. Anesth Analg 1994;79:892-8.
4. McPherson RW, Koehler RC, Traystman RJ. Hypoxia, alpha-2-adrenergic, and nitric oxide-dependent interactions on canine cerebral blood flow. Am J Physiol 1994;266:H476-82.
5. Peroutka SJ, Moskowitz MA, Reinhard JF Jr, Snyder SH. Neurotransmitter receptor binding in bovine cerebral microvessels. Science 1980;208:610-2.
6. Skarby T. Pharmacologic properties of prejunctional alpha-adrenoceptors in isolated feline middle cerebral arteries; comparison with the postjunctional alpha-adrenoceptors. Acta Physiol Scand 1984;122:165-74.
7. Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res 1984;319:69-101.
8. Bates D, Weinshilboum RM, Campbell RJ, Sundt TM Jr. The effect of lesions in the locus coeruleus on the physiological responses of the cerebral blood flow vessels in cats. Brain Res 1977;136:431-43.
9. Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha-2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology 1992;76:948-52.
10. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
11. Levasseur JE, Wei EP, Raper AJ, et al. Detailed description of a cranial window technique for acute and chronic experiments. Stroke 1975;6:308-317.
12. Zornow MH, Scheller MS, Sheehan PB, et al. Intracranial pressure effects of dexmedetomidine in rabbits. Anesth Analg 1992; 75:232-7.
13. Karlsson BR, Forsman M, Roald OK, et al. Effect of dexmedetomidine, a sensitive and potent alpha 2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs. Anesth Analg 1990;71:125-9.
14. Aisaka K, Kihara T, Koike M, et al. Effect of yohimbine on urethane-induced hyperglycemia in rats. Jpn J Pharmacol 1989; 49:523-7.
15. Tsukahara T, Taniguchi T, Usui H, et al. Sympathetic denervation and alpha adrenoceptors in dog cerebral arteries. Naunyn Schmiedebergs Arch Pharmacol 1986;334:436-43.
16. Coughlan MG, Lee JG, Bosnjak ZJ, et al. Direct coronary and cerebral vascular responses to dexmedetomidine. Significance of endogenous nitric oxide synthesis. Anesthesiology 1992;77: 998-1006.
17. Doze VA, Chen B, Tinkleberg JA, et al. Pertussis toxin and 4-aminopyridine differentially affect the hypnotic-anesthetic action of dexmedetomidine and phentobarbital. Anesthesiology 1990;73:304-7.
18. Maze M, Tranquilli W. Alpha-2 adrenoceptor agonists: defining the role in clinical anesthesia. Anesthesiology 1991;74:581-605.
19. 2. J Cereb Blood Flow Metab 1986;6:358-65.
20. Eisenach JC, Shafer SL, Bucklin BA, et al. Pharmacokinetics and pharmacodynamics of intraspinal dexmedetomidine in sheep. Anesthesiology 1994;80:1349-59.
21. Levin VA, Landahl HD. Pharmacokinetic approaches to drug distribution in the cerebrospinal fluid based on ventricular administration in beagle dogs. J Pharmacokinet Biopharm 1985;13: 387-403.
22. Busija DW. Sympathetic nerves reduce cerebral blood flow during hypoxia in awake rabbits. Am J Physiol 1984;247:H446-51.
23. Adams LM, Foote SL. Effects of locally infused pharmacological agents on spontaneous and sensory-evoked activity of locus coeruleus neurons. Brain Res Bull 1988;21:395-400.
24. 2-adrenergic agonist meetomidine on in vivo catechol activity in the rat rostral ventrolateral medulla (RVLM). Brain Res 1992;592:163-9.
25. Underwood MD, Iadecola C, Reis DJ. Lesions of the rostral ventrolateral medulla reduce the cerebrovascular response to hypoxia. Brain Res 1994;635:217-23.
26. Buchweitz E, Edelman NH, Weiss HR. Effects of locus coeruleus stimulation on regional cerebral oxygen consumtion in the cat. Brain Res 1985;325:107-14.
27. Donegan JH, Traystman RJ, Koehler RC, et al. Cerebrovascular hypoxic and autoregulatory responses during reduced brain metabolism. Am J Physiol 1985;249:H421-9.
28. 2-adrenergic antagonist atipamezole. Anesthesiology 1991;75:328-32.
29. 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993;79:306-12.
30. Hoffman WE, Baughman VL, Albrecht RF. Interaction of catecholamines and nitrous oxide ventilation during incomplete brain ischemia in rats. Anesth Analg 1993;77:908-12.
31. 2 adrenergic agonist, dexmedetomidine, selectively attenuates ischemia-induced increases in striatal norepinephrine concentrations. Brain Res 1993;627:325-9.
32. Gustafson I, Westerberg E, Wieloch T. Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J Cereb Blood Flow Metab 1990;10:885-94.
33. Gustafson I, Miyauchi Y, Wielock TW. Postischemic administration of idazoxan, an α-2 adrenergic receptor antagonist, decreases neuronal damage in the rat brain. J Cereb Blood Flow Metab 1989;9:171-4.
34. Gustafson I, Westerberg EJ, Wieloch T. Extracellular brain cor-tical levels of noradrenaline in ischemia: effects of desipramine and postischemic administration of idazoxan. Exp Brain Res 1991;86:555-61.